Here is how Bio-Rad Laboratories (BIO) and Certara, Inc. (CERT) have performed compared to their sector so far this year.

Introduction to Newborn Screening InstrumentsNewborn screening is a critical medical process that involves testing newborns for certain genetic, metabolic, and congenital conditions. The objective is ...

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through ...

S&P 500 Shake-Up: New Entrants Driving Market Momentum The S&P 500 is a widely recognized benchmark for the US stock market, and it has undergone reshuffling due to the quarterly rebalancing ...

Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Free Report) has been given an average rating of “Moderate Buy” by the five ...

The global nucleic acid testing market is witnessing unprecedented growth, with a market size of USD 3.7 billion in 2023, driven by a robust compound annual growth rate (CAGR) of 6.8%. By the end of ...

AliveDx’s CE mark for the systematic autoimmune rheumatic disease (SARD) assay marks its fifth approval in the past 18 months ...

GFP, expanding its portfolio of secondary antibodies for life science research. GFP is widely used to monitor protein ...